Yoshimasa Takahashi
Overview
Explore the profile of Yoshimasa Takahashi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
165
Citations
3135
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nishiyama A, Nogimori T, Masuta Y, Matsuura T, Kase T, Kondo K, et al.
Vaccines (Basel)
. 2025 Feb;
13(2).
PMID: 40006687
Current influenza A vaccines primarily induce neutralizing antibodies targeting the variable hemagglutinin (HA) head domain, limiting their effectiveness against diverse or emerging influenza A virus (IAV) subtypes. The conserved HA...
2.
Fujisawa M, Onodera T, Kuroda D, Kewcharoenwong C, Sasaki M, Itakura Y, et al.
NPJ Vaccines
. 2025 Feb;
10(1):39.
PMID: 39988605
Rabies vaccines require repeated immunization to robustly elicit neutralizing antibodies that prevent fatal diseases. Here, we analyzed rabies glycoprotein antibody repertoires at both polyclonal and monoclonal levels following repeated vaccination....
3.
Yamashita W, Chihara K, Azam A, Kondo K, Ojima S, Tamura A, et al.
Commun Biol
. 2025 Feb;
8(1):290.
PMID: 39987292
Bacteria possess numerous defense systems against phage infections, which limit phage infectivity and pose challenges for phage therapy. This study aimed to engineer phages capable of evading these defense systems,...
4.
Sasaki E, Asanuma H, Momose H, Maeyama J, Moriyama S, Nagata N, et al.
NPJ Vaccines
. 2025 Feb;
10(1):28.
PMID: 39934182
Adjuvants play a crucial role in enhancing vaccine efficacy. Although several adjuvants have been approved, there remains a demand for safer and more effective adjuvants for nasal vaccines. Here, we...
5.
Kochayoo P, Moriyama S, Kotaki R, Thawornpan P, Malee C, Leepiyasakulchai C, et al.
PLoS Pathog
. 2025 Jan;
21(1):e1012866.
PMID: 39847574
Expansion of atypical memory B cells (aMBCs) was demonstrated in malaria-exposed individuals. To date, the generation of P. vivax-specific aMBCs and their function in protective humoral immune responses is unknown....
6.
Takashita E, Shimizu K, Usuku S, Senda R, Okubo I, Morita H, et al.
Euro Surveill
. 2024 Dec;
29(50).
PMID: 39668762
An outbreak of influenza A(H1N1)pdm09 viruses exhibiting cross-resistance to oseltamivir and peramivir occurred in Yokohama, Japan, in September 2024. Among 24 students in a class, 11 were diagnosed with influenza...
7.
Takeuchi Y, Ishikawa E, Sato T, Shinkai M, Takahashi Y, Lu X, et al.
Int Immunol
. 2024 Dec;
PMID: 39665863
The pandemic outbreak of SARS-CoV-2 has threatened human health worldwide. Among protective immune reactions, T cell responses are diverse among individuals, which is related to the differences in severity. A...
8.
Azam A, Kondo K, Chihara K, Nakamura T, Ojima S, Nie W, et al.
Nat Commun
. 2024 Nov;
15(1):9586.
PMID: 39528469
Retrons are bacterial genetic elements that encode a reverse transcriptase and, in combination with toxic effector proteins, can serve as antiphage defense systems. However, the mechanisms of action of most...
9.
Yajima H, Anraku Y, Kaku Y, Kimura K, Plianchaisuk A, Okumura K, et al.
Nat Commun
. 2024 Oct;
15(1):8574.
PMID: 39375326
Since 2019, SARS-CoV-2 has undergone mutations, resulting in pandemic and epidemic waves. The SARS-CoV-2 spike protein, crucial for cellular entry, binds to the ACE2 receptor exclusively when its receptor-binding domain...
10.
Yamasaki M, Saso W, Yamamoto T, Sato M, Takagi H, Hasegawa T, et al.
Antiviral Res
. 2024 Aug;
230:105992.
PMID: 39181215
Given the worldwide risk for the outbreak of emerging/re-emerging respiratory viruses, establishment of new antiviral strategies is greatly demanded. In this study, we present a scheme to identify gapmer antisense...